• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Utilization of Neoaduvant Chemotherapy and Oncological Outcomes in Patients Undergoing Radical Cystectomy for Variant Histology Versus Pure Urothelial Bladder Cancer - A Retrospective Comparative Cohort Study.
Indian J Surg Oncol. 2025 Jun;16(3):753-761. doi: 10.1007/s13193-024-02138-y. Epub 2024 Nov 28.
2
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.根治性子宫切除术联合放化疗与单纯根治性子宫切除术治疗局部晚期宫颈癌的疗效比较
Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD010260. doi: 10.1002/14651858.CD010260.pub3.
3
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.对局部晚期宫颈癌女性患者进行子宫切除术并辅以放疗或化疗或两者联合治疗。
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
4
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
5
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?对于因恶性肿瘤导致骨缺损的患者，在重建下肢节段性切除时，采用带血管游离腓骨移植来增强照射后的自体骨移植，其骨愈合、功能及并发症发生率与无骨缺损且未进行增强的患者相比是否相当？
Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599.
6
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.治疗胶质母细胞瘤进展或复发的选择：网络荟萃分析。
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
8
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.晚期上皮性卵巢癌初始治疗中，术前新辅助化疗与手术加化疗的比较。
Cochrane Database Syst Rev. 2025 Feb 10;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub7.
9
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment.口腔和口咽癌的治疗干预措施：手术治疗。
Cochrane Database Syst Rev. 2023 Aug 31;8(8):CD006205. doi: 10.1002/14651858.CD006205.pub5.
10
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

Utilization of Neoaduvant Chemotherapy and Oncological Outcomes in Patients Undergoing Radical Cystectomy for Variant Histology Versus Pure Urothelial Bladder Cancer - A Retrospective Comparative Cohort Study.

作者信息

Jayanth S T, Debnath Abhik, Gowri Mahasampath, George Arun J P, Devasia Antony, Kumar Santosh, John Nirmal Thampi

机构信息

Department of Urology, CMC Vellore, Vellore, TN India.

Department of Biostatistics, CMC Vellore, Vellore, TN India.

出版信息

Indian J Surg Oncol. 2025 Jun;16(3):753-761. doi: 10.1007/s13193-024-02138-y. Epub 2024 Nov 28.

DOI:10.1007/s13193-024-02138-y
PMID:40687872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12267806/
Abstract

UNLABELLED

Prospective data on outcome of variant histology bladder cancer is scarce. We compared the neoadjuvant chemotherapy usage and oncological outcomes in patients undergoing radical cystectomy for variant versus pure urothelial histology bladder cancer. This was a retrospective comparative cohort study. Data was collected from the electronic database of our hospital from June 2009 to June 2018. Two hundred forty-one patients underwent radical cystectomy in the study period. Patients were divided into two groups (Group A - variant histology bladder cancer and Group B - pure urothelial histology). The primary outcome was overall survival. The secondary outcomes included recurrence free survival and complications. Of the 241 patients, 41 had variant histology. Histological variants were sarcomatoid (11), sarcoma (4), squamous cell (8), neuroendocrine (3), adenocarcinoma (8), and others (7). The median age was 59 years in both groups. The median duration of follow-up in Groups A and B was 12.5 and 24 months, respectively. NACT was given in 12 and 14% (Groups A and B). The median overall survival in Groups A and B was 24 (95% 14-33) and 40 months (95% 29-50), respectively (95% 25-50) ( = 0.12). The median OS trend is better with chemotherapy among both VH (NACT vs no NACT: not reached and 24 months) and UC (NACT vs no NACT: 40 and 36 months) groups. Margin positivity rate was significantly higher in Group A (12%) compared to Group B (3%) ( < 0.03). The recurrence free survival in Groups A and B was 16( 3-28) and 38( 23-52) months, respectively ( = 0.06). There was no difference in post-operative complications (Clavien Dindo) between the two groups ( = 0.59). Variant histology bladder cancers exhibit an aggressive behavior with early recurrences and a poorer overall survival compared to pure urothelial bladder cancer. Neoadjuvant chemotherapy tends to improve survival in both groups.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s13193-024-02138-y.

摘要